Preclinical Strategy
Development plans for pharmacology, toxicology, animal models, GLP studies and regulatory-enabling packages.
Regulatory · Development · Global Strategy
Accelerating medicines from concept to patients.
LINQ Pharma Consulting helps biopharmaceutical companies, government agencies and not-for-profit organizations move complex programs from preclinical development through regulatory approval and post-approval compliance.
End-to-end support
Integrated expertise across the product lifecycle.
We connect development science, regulatory strategy and execution so critical decisions are made with the end goal—successful global market access—in view.
CMC & Manufacturing
CMC strategy, process and analytical development, technology transfer, GMP readiness and manufacturing oversight.
Regulatory Strategy
Agency interaction strategy, briefing packages, meeting leadership, submissions and lifecycle regulatory planning.
Clinical Development
IND/CTA support, protocol and development strategy, GCP compliance and global clinical trial readiness.
Marketing Authorization
Dossier strategy and coordination for BLAs, NDAs, MAAs and other major market authorization applications.
Post-Approval Support
Lifecycle management, commitments, variations, labeling strategy and Phase 4 compliance support.
Development pathway
One strategic thread from early development through lifecycle management.
STAGE 1
Preclinical
Program architecture and regulatory-enabling studies.
STAGE 2
CMC
Process, analytics, manufacturing and quality strategy.
STAGE 3
Regulatory Entry
Agency meetings and IND/CTA submissions.
STAGE 4
Clinical
GCP, trial execution and evidence strategy.
STAGE 5
Approval & Beyond
Marketing application and lifecycle compliance.
LINQ Pharma Consulting
Need senior-level perspective on a critical development or regulatory decision?
We work as an extension of internal teams—bringing experienced, practical judgment to program strategy, agency engagement and execution.
Start a Conversation